Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Peanut allergy is the most common cause of fatal and near-fatal food-allergic reactions and egg allergy is among the two most common causes of food-induced anaphylaxis. The proposed research will explore the development of sensitization to these food(s) in infants based on maternal consumption or avoidance during pregnancy and breastfeeding.
Full description
The goals of this study include defining the role of egg and peanut consumption or avoidance during pregnancy and via human milk in food sensitization and identifying the underlying biological mechanisms leading to sensitization or tolerance. The study population will include 500 mother/infant dyads who plan to exclusively feed breastmilk to healthy infants. We expect approximately 25% will be recruited locally and the rest from across the United States. This is a national, parallel, two arm, one-to-one allocation, single blinded, randomized controlled trial. Each arm of the study defines maternal diet from 27 weeks gestation through their baby's fourth month with some consuming peanut and egg and some avoiding these foods.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
• o Subject must be able to understand and provide informed consent.
English-speaking adults, 18 years or older. (Spanish speaking adults may be included after consent document is translated and Spanish speaking study representatives are available to conduct and answer questions during informed consent process and for study follow up.)
Maternal consent must be provided for infants.
Pregnant women from the time pregnancy is confirmed until 27 weeks of gestation.
Self-reported at time of enrollment:
Intend to give their infant their own breast milk for more than 3 months.
Can confidently say they have eaten PN and egg and have tolerated consumption with no food allergy reactions.
Willing to be randomized to consumption or avoidance diet.
Uncomplicated pregnancy (no gestational diabetes, no preeclampsia, no hyperemesis gravidarum), self-reported at time of enrollment.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
500 participants in 2 patient groups
Loading...
Central trial contact
Allison W Leadley, MPH; Leanna Twohig, MS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal